Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today published its financial report on the first six months of 2026 (1 December 2025 – 31 May 2026) and reported on the course of business.
– Phase I dose escalation study with pamlectabart tismanitin (HDP-101) in multiple myeloma completed
– Dose escalation study has started at the recommended Phase II dose (RP2D) and is proceeding as planned
– Amendment of existing agreement with HealthCare Royalty and participation of Soleus Capital; payment of USD 20 million extends cash reach to mid-2027
– Partnered ADC programs with Takeda and Huadong are progressing successfully; milestone payments received from both parties
– Peter Willinger appointed new Chief Financial Officer
– Financial figures in line with planning